Cargando…

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

INTRODUCTION: Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eser, Kadir, Önder, Arif Hakan, Sezer, Emel, Çil, Timuçin, İnal, Ali, Öztürk, Banu, Erçolak, Vehbi, Duman, Berna Bozkurt, Çelik, Halil, Köşeci, Tolga, Kesen, Oğuzhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078089/ https://www.ncbi.nlm.nih.gov/pubmed/35525929 http://dx.doi.org/10.1186/s12885-022-09624-y

Ejemplares similares

Male Breast Cancer: Clinical, Demographical, and Pathological Features in a Cohort of 41 Patients
por: Koseci, Tolga, et al.
Publicado: (2021)

Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
por: Gulmez, Ahmet, et al.
Publicado: (2023)

Carbamazepine and Multiple Myeloma: Possible Interaction
por: Günaldı, Meral, et al.
Publicado: (2013)

Sweet Syndrome in a Patient with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Curious Lymphocyte/Neutrophil Fluctuations
por: Usul Afşar, Çiğdem, et al.
Publicado: (2013)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Bilateral Primary Adrenal Non-Hodgkin Lymphoma
por: Erçolak, Vehbi, et al.
Publicado: (2014)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Abdominal actinomycosis with multiple myeloma: A case report
por: ERCOLAK, VEHBI, et al.
Publicado: (2014)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
por: Mlinarić, Zvonimir, et al.
Publicado: (2022)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
por: Al-Ziftawi, Nour Hisham, et al.
Publicado: (2022)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

The therapeutic dilemma of peripartum cardiomyopathy
por: Biteker, Murat, et al.
Publicado: (2019)

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
por: Rath, Sushmita, et al.
Publicado: (2021)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Superscan Appearance of (68)Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer
por: Koç, Zehra Pınar, et al.
Publicado: (2022)

The Correlation of the Neutrophil-Lymphocyte Ratio and the Platelet-Lymphocyte Ratio With Pathological Findings in Neuroendocrine Tumors
por: Kulahci, Ozgur, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Comparative In Vitro Activities of First and Second-Generation Ceragenins Alone and in Combination with Antibiotics Against Multidrug-Resistant Klebsiella pneumoniae Strains
por: Ozbek-Celik, Berna, et al.
Publicado: (2019)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Comparison of aortic pressures and aortic elastic properties between patients with end-stage renal disease and healthy controls
por: Kalçık, Macit, et al.
Publicado: (2019)

A Case with Hypothyrodism Following Autologous Stem Cell Transplantation
por: Bozkurt Duman, Berna, et al.
Publicado: (2013)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Biventricular non-compaction cardiomyopathy with pulmonary stenosis, interatrial septal aneurysm, atrial septal defect, bradycardia, and mental retardation in a single case: A case report
por: Özlek, Bülent, et al.
Publicado: (2018)

Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?
por: Kucukoner, Mehmet, et al.
Publicado: (2012)

Cancers and Benign Processes on (68) Ga PSMA PET-CT Imaging Other than Prostate Cancer
por: Ozcan, Pinar Pelin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tbhh49kibvp7hee4sfg0rog4vg